OVERVIEW OF c-KIT AND ITS RTKs FAMILY
=====================================

c-KIT or CD117 is a member of class III transmembrane receptor tyrosine kinases (RTKs) along with platelet-derived growth factor receptors (PDGFRs), fms like tyrosine kinase 3 (FLT3)/CD135, and macrophage colony stimulating factor receptors (M-CSFRs). It was discovered in 1987 as a cellular homologue of viral oncogene *v-kit*, which was isolated from a feline retrovirus.[@B1][@B2] A variety of cell types were identified to express c-KIT including hematopoietic cells, germ cells, gastrointestinal (GI) tract Cajal cells, melanoma cells, B cell progenitors, and mast cells.

Wild-type c-KIT protein contains 976 amino acids (aa) divided into three main regions including an extracellular ligand-binding domain with 519 aa, a hydrophobic transmembrane domain with 23 aa, and an intracellular tail ([Fig. 1](#F1){ref-type="fig"}).[@B3][@B4] The extracellular domain consists of five immunoglobulin-like domains D1--D5, in which D1--D3 is responsible for stem cell factor (SCF) binding while D4--D5 contains motif for receptor dimerization. The 433 aa cytoplasmic region includes a juxta-membrane domain and a tyrosine kinase domain with an insertion of approximately 80 residues. Most of phosphorylation sites on c-KIT are located at the juxta-membrane region, the kinase insertion domain, and the C-terminal tail. Human c-KIT is encoded by a proto-oncogene located on the chromosome 4 at position of q11--12.[@B5] This 90 kb gene is transcribed and translated into a core protein of 110 kDa, which is subsequently heterogeneously N-linked glycosylated, mainly in the extracellular domain closest to the plasma membrane, before maturing to a size of 145--160 kDa.[@B2][@B6] c-KIT has four isoforms generated by alternative splicing mechanism.[@B7][@B8][@B9] The first two isoforms differ in the presence of a glycine-asparagine-asparagine-lysine (GNNK) tetra-peptide adjacent to the extracellular transmembrane domain. The other two relate to the presence or absence of a serine amino acid at position 715 (Ser715) in the kinase insertion region.

The ligand SCF of c-KIT is a hematopoietic cytokine, which signals to maintain survival of hematopoietic cells as well as to promote cell proliferation, differentiation and regulation of growth and development.[@B10] Upon binding to D1--D3 region of c-KIT, a homodimer of SCF induces a conformational change that enables a homotypic interaction between D4--D5 regions of two adjacent c-KIT molecules.[@B11][@B12] This dimerization allows a trans-phosphorylation of tyrosine residues in the intracellular region of each c-KIT monomer by the other, leading to signal transduction through plasma membrane. Many mutations in c-KIT have been found to perturb these characteristics. For example, a mutation in D4 at key residues disrupts the transmembrane regions of each monomer, thereby blocking the subsequent trans-phosphorylation of tyrosine kinase domains.[@B13] However, this kind of mutation dramatically reduces tyrosine phosphorylation but does not influence the dimerization. A comprehensive summary of *KIT* mutations and their respective clinical implications will be further discussed in detail later.

Downstream signaling pathways of c-KIT
--------------------------------------

Many studies have been done on various cell lines to describe different downstream signaling cascades of c-KIT, including mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway, PI3K/AKT pathway, Src family kinases pathway, phospholipases PLC-γ pathway, and JAK/STAT pathway.[@B14][@B15][@B16][@B17][@B18] These signaling pathways can be activated independently or concomitantly by c-KIT and they are integrated into a signaling circuit. Since different pathways relate to different cell types as well as cancer types, we will review in detail only pathways that are mostly well-known and researched on in c-KIT derived melanoma, which are MAPK/ERK pathway and PI3K/AKT pathway ([Fig. 2](#F2){ref-type="fig"}).

### MAPK/ERK pathway

Through trans-phosphorylation by SCF binding, c-KIT is activated and recruits adaptor proteins containing a Src homology 2 (SH-2) domain. This SH-2 protein will then associate with a guanine nucleotide exchange factor (GEF) that exchanges guanosine triphosphate (GTP) and guanosine diphosphate (GDP). This SH-2/GEF complex activates the G-protein RAS by transferring its GTP.[@B19] Activation of RAS leads to the activation of a serine/threonine protein kinase BRAF, which subsequently phosphorylates mitogen-activated protein kinase kinase1/2 (MAP2K1/2 or MEK1/2). MEK1/2, in turn, phosphorylates and activates ERK1/2. Several ERK1/2-activated transcription factors (TFs) induce the expression of genes related to cell proliferation, apoptosis, differentiation, adhesion, and mobility.[@B20][@B21]

### PI3K/AKT pathway

PI3K/AKT pathway is responsible for cell survival and regulation of apoptosis. This signaling pathway can be activated via two mechanisms: either directly through interaction with c-KIT at position Tyr721 or indirectly through scaffold protein Gab2 and adapter protein Grb2.[@B22][@B23] The p85 subunit of PI3K interacts with autophosphorylated c-KIT through its SH2 domain, changes conformation, and associates with the enzymatic p110 subunit to fully activate PI3K. That activation step also recruits PI3K to plasma membrane, placing it in close proximity of its lipid substrate, phosphatidylinositol 4,5-biphosphate (PIP2), which converts PIP2 to phosphatidylinositol 3,4,5-triphosphate (PIP3). The PIP~3~ then activates the pleckstrin homology (PH) domain, which contains proteins such as the serine/threonine kinase AKT.

AKT can activate several downstream proteins such as Bad, Foxo, and nuclear factor kappa-light chain enhancer of activated B cells (NF-κB) to interfere with the initiation of apoptosis and promote cell survival.[@B24][@B25][@B26][@B27] AKT also activates mTORC1 or mTor complex 1 (mTor, Raptor, GβL, PRAS40, and Deptor) through downstream pathway members like TSC1/2 and Rheb. This mTORC1 relates to melanocyte proliferation and migration.[@B28] The PI3K/AKT pathway can be inhibited by the phosphatase and tensin homolog (PTEN) gene. The PTEN protein removes one inorganic phosphate group from PIP3 to regenerate PIP~2~, which prevents the activation of AKT.

KIT interactions with other cytokines
-------------------------------------

It is well established that c-KIT interacts with various families of adaptor proteins, which contain multiple interaction domains, including SH2 and PH. Among growth factor receptorbound proteins, c-KIT was shown to interact with Grb7 at Tyr-936 position in the downstream signaling of cell migration.[@B29][@B30] Another member in this family, Grb10, was found to interact with c-KIT to facilitate its PI3K-kinase-dependent activation and following association with AKT.[@B31] CrkL, a member of Crk family, has its phosphorylation induced by c-KIT and can interact with the ubiquitin E3 ligase c-Cbl.[@B32] Activation of c-KIT can also trigger the binding to its juxta-membrane region of Dok1, an adaptor that can interact with many signaling proteins such as Abl, SHIP, PLCγ1, and CrkL.[@B33] Another interactor of c-KIT, Lnk, may negatively regulate function of c-KIT as *lnk*^−/−^ mice had an enhanced hematopoiesis.[@B34]

Apart from adaptor proteins, c-KIT can interact with and facilitate functions of many different cytokines. For examples, in primary mast cells, SCF-induced activation of c-KIT is required to evoke optimal IL-33-induced cytokine production.[@B35] c-KIT can also affect erythropoiesis as it can replace erythropoietin (Epo) to activate its receptor (Epo-R) by tyrosine phosphorylation and induce maturation of progenitors.[@B36] Similar with the interaction between c-KIT and Epo-R, the interaction with IL-7 of c-KIT can indirectly stimulate Jak-Stat pathway in T-lymphoid cells under the absence of Stat5 activation.[@B37] In myeloid cell line, interestingly, members of the transmembrane 4 superfamily (TM4SF), including CD9, CD63, and CD81, show their physical association and serve as negative modulators of c-KIT, thus, regulating its sensitivity to Steel factor (SLF) in hematopoietic progenitors.[@B38]

*KIT* mutations in melanoma
---------------------------

Dysregulation of c-KIT can affect cell proliferation, tumor growth, and metastasis in various cancer types such as gastrointestinal stromal tumors (GIST), leukemia (the first tumor found linked to *KIT* mutation), lung cancer, acute myeloid leukemia, and melanoma.[@B3][@B7][@B39][@B40] In fact, *KIT* mutations (mainly in-frame deletions of exon 11) are found in 80% of GIST tumors.[@B41][@B42] Apart from gene amplifications, *KIT* mutations in melanoma are almost all missense substitutions and widely distributed ([Fig. 3](#F3){ref-type="fig"}). [Table 1](#T1){ref-type="table"} shows a catalogue of 47 recorded *KIT* mutations based on data collected from a pooled analysis of 1635 patients samples from 12 recent melanoma genomics studies using cBioPortal ([www.cbioportal.org](https://www.cbioportal.org)) and several separate studies.[@B43][@B44][@B45][@B46][@B47][@B48][@B49][@B50][@B51][@B52][@B53][@B54] *KIT* mutations are identified in 3% of all melanomas and more specifically in 36% of acral melanomas, 39% of mucosal melanomas, and 28% of melanomas on chronically sun-damaged (CSD) skin but none in melanomas on skin without CSD or non-CSD (NCSD).[@B46] About 70% of *KIT* mutations in melanoma are localized to exon 11, most often a lysine-to-proline mutation at codon 576 (L576P), and to exon 13, most often a methionine-to-glutamic acid mutation at codon 642 (K642E). L576P affects the juxta-membrane domain and K642E affects a kinase domain. Both mutations lead to constitutive activation of c-KIT tyrosine kinase activity and subsequent induction of both MAPK and PI3K/AKT pathways.[@B55] Interestingly, mutations in *KIT* almost never occur in conjunction with *BRAF* (*V600E*) and *NRAS* (*G12/Q61*) mutations thereby suggesting an epistatic relationship.[@B56] Melanomas without these recurrent alterations in *BRAF* and *NRAS* have a significant enrichment for either *KIT* mutations or alterations in *NF1*, a downstream modulator in c-KIT/MITF signaling axis.[@B48]

CLINICAL IMPLICATIONS OF *KIT* MUTATIONS
========================================

Correlations between clinical features and *KIT* mutations
----------------------------------------------------------

The *KIT* mutation rate and its association with various clinicopathological features remains controversial as results of different studies are inconsistent. Here, we summarize the data from Gong, et al\'s 2018 meta-analysis[@B57] of the clinical implications of *KIT* mutations ([Table 2](#T2){ref-type="table"}). In this analysis, selected studies must satisfy three inclusion criteria: 1) *KIT* mutations detected in the tissue samples of human melanoma, but not in cell lines, 2) the incidence of *KIT* mutations according to clinicopathologic parameters was described in detail, and 3) studies were carried out on humans and published in English. This study collected data from 497 out of 5224 patients harboring *KIT* mutations, comprising 360 Asian patients and 137 White patients.

The authors reported that *KIT* mutations are more commonly found in older patients (≥60 years old) \[odds ratio (OR)=1.296, 95% confidence interval (CI): 1.025--1.641; *p*=0.031\] and are positively associated with both mucosal melanomas (OR=1.363, 95% CI: 1.094--1.697; *p*=0.006) and acral melanomas (OR=1.374, 95% CI: 1.123--1.682; *p*=0.002). When stratified by race, KIT was significantly associated with mucosal melanoma in White patients and acral melanoma in Asian patients. Additionally, a negative association was detected between *KIT* mutations and NCSD melanomas in both populations. However, there was a positive association between *KIT* mutations and CSD melanomas overall (OR=1.880, 95% CI: 1.127--3.136; *p*=0.016). *KIT* mutations are usually not found in melanomas that develop on the extremities and not correlated with melanoma on head/neck or trunk. Analyses also showed no significant relationship between *KIT* mutations and sex, Breslow thickness (either \>1 mm or \>4 mm), histological types, ulceration, mitotic rate, and tumor stages.

Overall, this meta-analysis documented a close association between *KIT* mutations and older age, acral mucosal subtypes of melanoma, and CSD sites, but did not find an association with histological subtypes or tumor stage. However, the results of this study are limited by the number of published data as well as the wide distribution of *KIT* mutations in various exons. The clinical implications of *KIT* mutations are informative clues for developing individualized therapies for patients, which will be reviewed in the next section.

Therapeutic trials of c-KIT inhibitors and success rates in melanomas
---------------------------------------------------------------------

A variety of kinase inhibitors have been developed exploring c-KIT as a therapeutic target in melanoma, but not all drugs have been approved for clinical trials. In this section, we summarize data from 13 studies that reported the success rates of four widely used c-KIT inhibitors in melanoma treatments. Summary of those clinical trials in sample size, objective response rate (ORR), disease control rate (DCR), median progression-free survival (PFS), and median overall survival (OS) is shown in [Table 3](#T3){ref-type="table"}.

### Imatinib

Imatinib, or imatinib mesylate, which was initially developed as an inhibitor of the BCR-ABL fusion protein and PDGFR, was found to also inhibit c-KIT and considered an effective drug for treatment of patients with GIST.[@B58][@B59] Clinical experience in four single-arm, open-label phase II trials of imatinib[@B44][@B60][@B61][@B62] will be compared. The most recent study among these screened 78 patients for response after continuous treatment with 400 mg/day imatinib until intolerable toxicities or disease progression occurred. Mutations in patients were widely distributed in exons 9, 11, 13, 17, and 18, with 60.2% of mutations occurring in exon 11 or 13. L576P and K642E accounted for 24.3% of all mutations. The median PFS in the evaluable cohort was 4.2 months (95% CI: 1.9--6.4 months), and median OS was 13.1 months (95% CI: 9.6--16.7 months). A range of durability was recorded with 17 partial response (PR) patients, 30 stable disease (SD) patients, and 29 patients showing progressive disease (PD). Differences were found between patients with *KIT* mutations. Patients with *KIT* mutations in exon 11 or 13 had ORR of 24.4% and DCR of 66.7% while those for the group of other alterations had the rate of 19.4% and 54.8% respectively. This study observed generally mild to moderate adverse events (AEs), including edema (50%), rash (18%), fatigue (9%), anorexia (7%), nausea (5%), and neutropenia (2%). The additional three studies showed consistent results. These studies started with high dose of imatinib (400 mg twice a day), which was commonly associated with grades 3--4 AEs such as lymphopenia, anemia, erythema multiforme, and vomiting. Among four studies, complete responses (CRs) were only observed in the earliest study of Carvajal group with two patients durable for 95 and 94 weeks. Both of them had the exon 11 L576P mutation as well as amplification of *KIT*.[@B44]

### Nilotinib

Nilotinib is another small kinase inhibitor with comparable or greater potency than imatinib in targeting *KIT* mutations.[@B63] Five studies were conducted using this drug, in which all patients received orally nilotinib 400 mg twice a day.[@B56][@B64][@B65][@B66][@B67] The most recent study was a phase II clinical trial conducted by the French Skin Cancer Network on 25 patients.[@B65] At 6 months after nilotinib initiation, only four patients were responsive to nilotinib (ORR: 16%, 90% CI: 5.6--33.0%), including one CR patient and three PR patients. Out of the other 21 patients, six experienced progression and 15 died with an estimated PFS of 6.0 months and a median OS of 13.2 months (95% CI: 5.6--19.9 months). Of note, patients with CR or PR had mutations in exon 11 or 13 with overall response rate of 26%, median PFS of 6 months (95% CI: 3--46.8), and median OS of 14.4 months (95% CI: 9.97--not reached). Among patients, 56% experienced grade 3 drug-related AEs such as fatigue, rash, increased aspartate transaminase/alanine transaminase or cholestasis, and nausea. The author also observed reduced phosphorylated STAT3 in nilotinib treated *KIT*-mutated cell lines, suggesting that the JAK/STAT pathway can be downregulated by c-KIT inhibition and thus, associated with tumor response. However, additional mechanistic studies and molecular profiling are required, as nilotinib also targets PDGFR and ABL, which can both signal through STAT3. Other studies were conducted in patients with or without prior targeted KIT therapy. In the study of 19 patients, patients with L576P mutation showed a 25% ORR and 50% DCR while those for K642E mutation were 25% and 75% respectively.[@B56] Of note, this study recorded two patients with reduction in size of brain metastases after nilotinib treatment by magnetic resonance imaging scanning.

### Dasatinib

Dasatinib is also a c-KIT inhibitor, which also targets Src family kinases (c-Src, YES, LCK, and FYN), BCR-ABL, PDGFR-β, and EPHA2.[@B68] Two studies of 36 and 22 evaluable patients respectively were conducted to assess clinical efficacy of dasatinib in *KIT*-mutated melanoma treatment.[@B69][@B70] Both studies treated patients with various starting doses of dasatinib but eventually fixed at 70 mg twice a day due to toxicity. No CR case was observed in either study. In the first study, only two patients showed PR lasting 64 and 24 weeks, causing an ORR of 5%.[@B70] Meanwhile, in the second study, four PRs and seven SDs were observed. Common grade 3 AEs were recorded, including fatigue (13%), dyspnea (12%), nausea (11%), anemia (7%), pleural effusion (5%), etc.

### Sunitinib

Sunitinib, which targets both c-KIT and vascular endothelial growth factor receptors (VEGFRs), is also approved for treating melanoma. Sunitinib was examined in two studies of 10 and 31 evaluable patients harboring *KIT* mutations in 2012 and 2015, respectively.[@B71][@B72] Both of studies started with sunitinib 50 mg daily before reducing to 37.5 and 25 mg per day. One CR with 15 months of durability was observed in the 2012 study. However, the 2015 study recorded no CR but observed 13% PR and 26% SD, which accounted for a DCR of 39%. The median PFS and median OS for the overall population in this study were 1.3 months (95% CI: 1.2--1.4) and 4.3 months (95% CI: 1.0--7.6), respectively. Most commonly recorded grade 3--4 AEs were asthenia (28%), thrombocytopenia (15%), anorexia (10%), and neutropenia (15%).

Several other kinase inhibitors targeting c-KIT were also clinically tested and recorded in case reports. For example, a patient with primary esophageal melanoma harboring *KIT* mutation in exon 11 showed significant response when being treated with oral masitinib.[@B73] Masitinib treatment caused dysphagia and odynophagia disappeared within 1 week and reduced size of brain metastatic lesions and visceral lesions in the following month. Another example is a 79-year-old man at stage IV M1b metastatic anal mucosal melanoma showing CR upon sorafenib therapy.[@B74]

Epigenetic regulation of *KIT*
------------------------------

Several up/down regulations of *KIT* expression are caused by epigenetic changes, which includes DNA methylation and histone modifications. For example, in cardiac progenitor cells, *KIT* is upregulated via action of stromal cell-derived factor-1α (SDF-1α). SDF-1α, combined with CXCR4, inhibits expression and global activity of DNA methyltransferase (DNMT), which then leads to demethylation of c-KIT gene.[@B75] In *KIT*-mutated mast cells, histone deacetylase inhibitors (HDACi) can decrease *KIT* mRNA levels, total c-KIT protein as well as cell surface c-KIT, followed later by major mast cell apoptosis.[@B76] Some breast cancer cell lines lack the c-KIT expression due to hypermethylation of *KIT* promoter and treating these cell lines with methyltransferase inhibitor such as 5Aza-2dC can boost the level of *KIT* mRNA.[@B77] *KIT* methylation is also recorded in squamous cell carcinoma of uterine cervix that overexpress c-KIT.[@B78][@B79] The increased methylation of CpG islands in these skin cancer cells might interfere with the binding of CTCF repressor with *KIT* promoter. In GIST, a repressive complex named PRC \[polycomb group (PcG) repressive complex\] can reversibly suppress *KIT* expression via various histone modifications such as H3K27me3 and H2AK119ub1.[@B80] In cutaneous melanoma, intriguingly, the presence of SCF leads to reduced *KIT* expression and increased methylation density at the *KIT* promoter.[@B81] However, this epigenetic change shows no significant correlations with common genetic drivers such as BRAF, NRAS, and PTEN. This suggests that *KIT* may have a tumor-suppressive function in cutaneous melanoma.[@B82][@B83][@B84] Supporting this tumorsuppressing role of *KIT* in melanoma, the hypermethylation of *KIT* is also associated with a lower OS rate, even when *BRAF* (*V600E*) is included for the survival risk prediction.[@B85] Additionally, *KIT* is also found to be inhibited by microRNAs, including miR-221 and miR-222, which leads to differentiation blockade of the melanoma cells and subsequent proliferation.[@B86] However, these microRNAs are repressed by a TF called promyelocytic leukemia zinc finger (PLZF); therefore, the silencing of PLZF can be a driver of cutaneous melanoma.

On the other hand, considering *KIT* as an oncogene, the epigenetic regulation of *KIT* is related to enhancers, those are differentially methylated regions (eDMRs) as melanomas progress from normal to primary tumors and then to metastases.[@B87] Bell, et al.[@B87] showed that the methylation patterns of eDMRs not only contributes to melanoma progression by overexpressing *KIT* but also distinguishes patient survival rates.

CONCLUSION
==========

Overall, based on data from various studies and case reports, we created a catalogue of *KIT* mutations, though not sufficient, and their mostly associated melanoma subtypes. An understanding of mutational classes in melanoma will facilitate appropriate personalized treatments. Additionally, *KIT* mutations present distinct correlation with a number of different clinicopathologic features. *KIT*-mutated harboring melanomas are closely associated with older age, and acral, mucosal, or CSD sites but not with other histological parameters or tumor stage or sex. Intriguingly, no significant difference is recorded in the clinical association with *KIT* mutations between White populations and Asian populations although *KIT* mutation rate is lower in the latter one.

Upon treatment of melanoma subtypes, clinical efficacy in treating *KIT*-mutated melanoma has been evaluated with various small-molecular inhibitors of c-KIT, including imatinib, nilotinib, dasatinib, and sunitinib. Data collected from studies over 20 years has provided substantially critical insights into the therapeutic trials of these drugs and their success rate. However, in many cases, most patients eventually experience disease progression. One of possible explanation for this drug resistance is the frequent presence of brain and central nervous system metastases in advanced melanoma as the drug penetration is limited in these areas. With this being said, numerous additional investigational studies exploring c-KIT as a therapeutic target in combination therapy against melanoma. For instance, co-targeting c-KIT and its downstream pathways might be a plausible solution to control tumor progression. On the other hand, c-KIT inhibition showed its potential synergy with the immunological checkpoint blockade to develop antitumor effect.[@B88][@B89] This is due to the ability of c-KIT inhibitors to enhance immune response such as increased T-cell activation and natural killer cell clonal expansion.[@B90][@B91]
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###### Catalogue of KIT Mutations in Melanomas
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  No   KIT mutation       Mutation type   Variation type   Copy number          Exon location   Corresponding region               Cancer type
  ---- ------------------ --------------- ---------------- -------------------- --------------- ---------------------------------- ----------------------------------------------
  1    G32V               Missense        G → T            ShallowDel           2               Extracellular domain               Cutaneous melanoma
  2    P36Q               Missense        C → A            Gain                 2               Extracellular domain               Cutaneous melanoma
  3    V50L               Missense        G → C            \-                   2               Extracellular domain               Desmoplastic melanoma
  4    S106F              Missense        C → T            Diploid              2               Extracellular domain               Cutaneous melanoma
  5    S123F              Missense        C → T            Diploid              3               Extracellular domain               Cutaneous melanoma
  6    L160V              Missense        T → G            \-                   3               Extracellular domain               Cutaneous melanoma
  7    A207S              Missense        G → T            Diploid              3               Extracellular domain               Cutaneous melanoma
  8    G226W              Missense        G → T            Gain                 4               Extracellular domain               Cutaneous melanoma
  9    T245M              Missense        C → T            Diploid              4               Extracellular domain               Cutaneous melanoma
  10   P363S              Missense        C → T            Diploid              6               Extracellular domain               Cutaneous melanoma
  11   G445E              Missense        G → A            \-                   8               Extracellular dimerization motif   Cutaneous melanoma
  12   S451C              Missense        C → G            Gain                 9               Extracellular dimerization motif   Cutaneous melanoma
  13   P456Q              Missense        C → A            \-                   9               Extracellular dimerization motif   Cutaneous melanoma
  14   P467Q              Missense        C → A            Diploid              9               Extracellular dimerization motif   Cutaneous melanoma
  15   N463S              Missense        \-               \-                   9               Extracellular dimerization motif   Mucosal melanoma
  16   Y503del_insFAH     In-frame Ins    \- → TTGCCC      Amp                  9               Extracellular dimerization motif   Cutaneous melanoma
  17   V532I              Missense        G → A            Diploid              10              Transmembrane domain               Melanoma
  18   M541L              Missense        A → C            ShallowDel           10              Transmembrane domain               Melanoma of unknown primary
  19   W557R              Missense        T → A/C          Amp                  11              Juxta-membrane domain              Acral, mucosal, cutaneous melanoma
  20   V559A              Missense        T → C            Diploid/ShallowDel   11              Juxta-membrane domain              Acral, mucosal, cutaneous melanoma
  21   V559D              Missense        T → A            \-                   11              Juxta-membrane domain              Acral, mucosal melanoma
  22   V569A              Missense        T → C            \-                   11              Juxta-membrane domain              Cutaneous melanoma
  23   Y570H              Missense        \-               \-                   11              Juxta-membrane domain              CSD melanoma
  24   Y570_L576del       In-frame Del    TT → -           \-                   11              Juxta-membrane domain              Cutaneous melanoma
  25   L576P              Missense        T → C            Amp                  11              Juxta-membrane domain              Acral, mucosal melanoma
  26   W582L              Missense        G → T            ShallowDel           11              Juxta-membrane domain              Cutaneous melanoma
  27   K642E              Missense        A → G            Amp/Gain/Diploid     13              TKI domain/ATP-binding pocket      Acral, mucosal, cutaneous melanoma
  28   V654A              Missense        \-               \-                   13              TKI domain/ATP-binding pocket      Mucosal melanoma
  29   T666I              Missense        C → T            \-                   14              Kinase insertion domain            Cutaneous melanoma, lentigo maligna melanoma
  30   F681I              Missense        T → A            \-                   14              Kinase insertion domain            Desmoplastic Melanoma
  31   L706F              Missense        C → T            Diploid              14              Kinase insertion domain            Cutaneous melanoma
  32   M722I              Missense        G → T            Diploid              15              Kinase insertion domain            Cutaneous melanoma
  33   Q775K              Missense        C → A            Diploid              16              Kinase domain                      Cutaneous melanoma
  34   G803C              Missense        G → T            Diploid              17              Kinase domain                      Cutaneous melanoma
  35   R815_D816delinsS   IF del                           Diploid              17              Kinase domain                      Cutaneous melanoma
  36   D816N              Missense        G → A            Amp                  17              Kinase domain                      Cutaneous melanoma
  37   D820Y              Missense        \-               \-                   17              Kinase domain                      Mucosal melanoma
  38   N822I              Missense        A → T            Amp                  17              Kinase domain                      Cutaneous melanoma
  39   N822K              Missense        T → G            Gain                 17              Kinase domain                      Cutaneous melanoma
  40   N822Y              Missense        A → T            Amp                  17              Kinase domain                      Cutaneous melanoma
  41   A829P              Missense        \-               \-                   18              Kinase domain                      Mucosal melanoma
  42   P838L              Missense        \-               \-                   18              Kinase domain                      Acral melanoma
  43   V8521              Missense        \-               \-                   18              Kinase domain                      Mucosal melanoma
  44   A895T              Missense        G → A            \-                   19              Kinase domain                      Cutaneous melanoma
  45   P911L              Missense        C → T            \-                   20              Kinase domain                      Cutaneous melanoma
  46   R956Q              Missense        G → A            \-                   21              C-terminal tail                    Melanoma
  47   S967F              Missense        CC → TT          \-                   21              C-terminal tail                    Cutaneous melanoma

CSD, chronically sun-damaged.

###### Associations between *KIT* Mutations and Various Clinicopathological Features/Races of Melanomas

![](ymj-61-562-i002)

  Clinicopathologic characteristics   OR      95% CI          *p* value   Association with *KIT* mutation
  ----------------------------------- ------- --------------- ----------- ---------------------------------
  Age (≥60 yr)                                                            
   Asian                              1.349   1.056--1.723    0.017       Positive
   White                              0.795   0.337--1.879    0.602       None
   Overall                            1.296   1.025--1.641    0.031       Positive
  Sex                                                                     
   Asian                              1.134   0.910--1.412    0.264       None
   White                              0.860   0.426--1.735    0.674       None
   Overall                            1.106   0.897--1.364    0.347       None
  Mucosal melanoma                                                        
   Asian                              1.080   0.842--1.386    0.545       None
   White                              3.003   1.895--4.758    \<0.001     Positive
   Overall                            1.363   1.094--1.697    0.006       Positive
  Acral melanoma                                                          
   Asian                              1.361   1.087--1.702    0.007       Positive
   White                              1.435   0.901--2.286    0.128       None
   Overall                            1.374   1.123--1.682    0.002       Positive
  Cutaneous melanoma with NCSD                                            
   Asian                              0.613   0.424--0.886    0.009       Negative
   White                              0.094   0.018--0.500    0.006       Negative
   Overall                            0.562   0.392--0.805    0.002       Negative
  Cutaneous melanoma with CSD                                             
   Asian                              1.643   0.962--2.806    0.069       None
   White                              7.791   1.370--44.291   0.021       Positive
   Overall                            1.880   1.127--3.136    0.016       Positive
  Melanoma on the extremities         0.294   0.105--0.820    0.019       Negative
  Breslow thickness                                                       
   \>1 mm                             0.910   0.586--1.413    0.674       None
   \>4 mm                             1.177   0.928--1.492    0.179       None
  Ulceration                          0.968   0.772--1.215    0.781       None

CSD, chronically sun-damaged; NCSD, non-CSD; OR, odds ratio; CI, confidence interval.
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  No.   KIT inhibitors (mg)   No. of patients   ORR (%)   DCR (%)   Median PFS (months)   Median OS (months)   Study
  ----- --------------------- ----------------- --------- --------- --------------------- -------------------- ------------------------
  1     IMA 400 BID           25                16        36        2.8                   10.7                 Carvajal, et al.[@B44]
  2     IMA 400 QD or BID     43                23.3      53.5      3.5                   12.0                 Guo, et al.[@B60]
  3     IMA 400 QD or BID     24                29.2      50        3.7 (TTP)             12.5                 Hodi, et al.[@B61]
  4     IMA 400 QD            78                21.8      60.3      4.2                   13.1                 Wei, et al.[@B62]
  5     NIL 400 BID           9                 22.2      77.8      2.5                   \-                   Cho, et al.[@B64]
  6     NIL 400 BID           19                15.8      52.6      3.3 (TTP)             9.1                  Carvajal, et al.[@B56]
  7     NIL 400 BID           42                16.7      57.1      3.3                   11.9                 Lee, et al.[@B67]
  8     NIL 400 BID           42                26.2      73.8      4.2                   18.0                 Guo, et al.[@B66]
  9     NIL 400 BID           25                16        64        6.0                   13.2                 Delyon, et al.[@B65]
  10    DAS 70 BID            36                5         \-        2.0                   13.8                 Kluger, et al.[@B70]
  11    DAS 70 BID            22                18.2      50        2.1                   7.5                  Kalinsky, et al.[@B69]
  12    SUN 50 QD             10                40        50        \-                    \-                   Minor, et al.[@B72]
  13    SUN 50 QD             31                13        39        1.3 (TTP)             4.3                  Decoster, et al.[@B71]

ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; BID, twice daily; QD, once daily; IMA, imatinib; NIL, nilotinib; DAS, dasatinib; SUN, sunitinib; TTP, time to progression.
